Stock Analysis on Net

Merck & Co. Inc. (NYSE:MRK)

$24.99

Analysis of Goodwill and Intangible Assets

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Goodwill and Intangible Asset Disclosure

Merck & Co. Inc., balance sheet: goodwill and intangible assets

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Goodwill
Product rights
IPR&D
Trade names
Licenses and other
Other acquired intangibles, gross carrying amount
Accumulated amortization
Other acquired intangibles, net
Goodwill and other intangibles

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The analysis of the financial data reveals several notable trends in the intangible assets over the five-year period.

Goodwill
Goodwill values show a modest increase from US$20,238 million in 2020 to US$21,668 million in 2024, indicating relative stability with minor fluctuations during the period.
Product Rights
Product rights demonstrate a significant decline from US$45,087 million in 2020 to approximately US$23,555-$23,988 million in the subsequent years, with a slight recovery to US$29,988 million in 2024. This reflects a substantial reduction in the asset value during 2021, stabilizing in the following years with some growth towards the end of the period.
IPR&D (In-Process Research and Development)
IPR&D shows a sharp increase from US$3,228 million in 2020 to a peak of US$9,281 million in 2021, followed by gradual decreases to US$430 million by 2024. This pattern suggests a significant investment or acquisition in early 2021, with subsequent amortization or impairment reducing the carrying amount steadily.
Trade Names
Trade names remain stable across the period, maintaining values around US$2,880 million, implying consistent valuation without material disposals or impairments.
Licenses and Other
This category shows a steady increase from US$6,400 million in 2020 to US$8,863 million in 2024, indicating ongoing additions or revaluations contributing positively to the intangible assets.
Other Acquired Intangibles, Gross Carrying Amount
The gross carrying amount of other acquired intangibles decreases notably from US$57,597 million in 2020 to around US$41,603-$42,162 million in the latter years, reflecting disposals, amortization, or impairments over time.
Accumulated Amortization
Accumulated amortization displays a consistent increase in absolute terms, moving from -US$42,993 million in 2020 to -US$25,792 million in 2024, which likely represents cumulative amortization charged against intangible assets, indicating ongoing expense recognition against these assets.
Other Acquired Intangibles, Net
The net value of other acquired intangibles rises sharply to US$22,933 million in 2021 from US$14,604 million in 2020 but then declines steadily to US$16,370 million by 2024. This pattern mirrors the gross and accumulated amortization figures, pointing to initial asset acquisitions followed by regular amortization.
Goodwill and Other Intangibles
The aggregate of goodwill and other intangibles increases from US$34,842 million in 2020 to a peak of US$44,197 million in 2021, before gradually declining to US$38,038 million in 2024. This reflects the overall dynamic in the portfolio of intangible assets, with significant additions or revaluations early in the period followed by amortization and possible asset attrition thereafter.

Overall, the reported data suggest a phase of considerable intangible asset accumulation around 2021, particularly in product rights and IPR&D, accompanied by rising amortization expenses. Subsequently, there is a general trend of amortization and value decline across most intangible categories, except for licenses and similar rights, which show gradual growth. The stability in goodwill and trade names indicates less fluctuation in those asset classes, contributing to the overall retained value of intangible assets in the later periods.


Adjustments to Financial Statements: Removal of Goodwill

Merck & Co. Inc., adjustments to financial statements

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Adjustment to Total Assets
Total assets (as reported)
Less: Goodwill
Total assets (adjusted)
Adjustment to Total Merck & Co., Inc. Stockholders’ Equity
Total Merck & Co., Inc. stockholders’ equity (as reported)
Less: Goodwill
Total Merck & Co., Inc. stockholders’ equity (adjusted)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The data indicates that the reported total assets of the company have generally increased over the observed period, rising from US$91,588 million at the end of 2020 to US$117,106 million by the end of 2024. Despite this overall upward trend, a slight decrease can be observed in 2023 compared to 2022, where total assets declined from US$109,160 million to US$106,675 million, before rising again in 2024.

When considering the adjusted total assets, which presumably exclude goodwill or other adjustments, the values also show an increasing trend from US$71,350 million in 2020 to US$95,438 million in 2024. Similar to the reported total assets, there is a downward movement in 2023 compared to 2022, with adjusted assets decreasing from US$87,956 million to US$85,478 million, followed by a recovery in 2024.

The reported total stockholders' equity reflects a notable increase between 2020 and 2022, growing from US$25,317 million to US$45,991 million. However, in 2023, stockholders' equity experienced a marked decline to US$37,581 million, before rebounding to US$46,313 million in 2024. This pattern suggests some volatility during these years, possibly linked to operational results or equity transactions.

Adjusted stockholders' equity, which likely removes the effects of goodwill or intangible assets, shows a similar trend with less magnitude. It increased significantly from US$5,079 million in 2020 to US$24,787 million in 2022, declined sharply to US$16,384 million in 2023, and then increased again to US$24,645 million in 2024. The disparity between reported and adjusted equity highlights the impact of goodwill and other adjustments on the company’s equity base.

Overall, both reported and adjusted metrics demonstrate growth over the five-year span, with a noticeable dip in 2023 suggesting a temporary setback or adjustment period. The trends in adjusted figures show more volatility relative to reported figures, indicating that goodwill and similar assets significantly influence the company’s reported financial position. The rebound in 2024 across all metrics suggests renewed growth or recovery following the prior year's decline.


Merck & Co. Inc., Financial Data: Reported vs. Adjusted


Adjusted Financial Ratios: Removal of Goodwill (Summary)

Merck & Co. Inc., adjusted financial ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Total Asset Turnover
Reported total asset turnover
Adjusted total asset turnover
Financial Leverage
Reported financial leverage
Adjusted financial leverage
Return on Equity (ROE)
Reported ROE
Adjusted ROE
Return on Assets (ROA)
Reported ROA
Adjusted ROA

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


The analysis of the financial metrics over the five-year period reveals various notable trends and fluctuations in both reported and goodwill adjusted figures.

Total Asset Turnover
The reported total asset turnover ratio shows a slight decline from 0.52 in 2020 to 0.46 in 2021, followed by an increase to 0.54 in 2022 and a peak at 0.56 in 2023. It then marginally declines to 0.55 in 2024. The adjusted total asset turnover follows a similar pattern but remains consistently higher than the reported figures, indicating the positive impact of goodwill adjustments. This ratio starts at 0.67 in 2020, dips to 0.58 in 2021, then rises to 0.67 in 2022, reaching a high of 0.70 in 2023, before decreasing slightly to 0.67 in 2024. Overall, asset utilization efficiency improved after 2021, with a slight stabilization towards the end of the period.
Financial Leverage
Reported financial leverage exhibits a decreasing trend initially, dropping from 3.62 in 2020 to 2.37 in 2022, suggesting a reduction in reliance on debt or equity magnification. However, it increased again to 2.84 in 2023 before falling to 2.53 in 2024. In contrast, adjusted financial leverage starts very high at 14.05 in 2020, sharply decreasing to 4.99 in 2021, and further to 3.55 in 2022. Similar to the reported figure, it increased to 5.22 in 2023 before declining to 3.87 in 2024. The adjusted leverage is significantly higher than reported values, reflecting the effect of goodwill on the capital structure measurement. The overall pattern points to a general reduction in leverage over time, with some volatility in the middle years.
Return on Equity (ROE)
Reported ROE demonstrates fluctuations with a rising trend from 27.91% in 2020 to 34.17% in 2021, a slight decline to 31.57% in 2022, a steep fall to 0.97% in 2023, and a rebound to 36.96% in 2024. Adjusted ROE follows a broadly similar trajectory but on a much higher scale, starting from an exceptionally high 139.14% in 2020, falling sharply to 77.12% and then 58.58% in the following years, with a marked dip to 2.23% in 2023 before recovering to 69.45% in 2024. These variations suggest substantial volatility in profitability drivers and a significant impact of goodwill adjustments on shareholder returns, especially noticeable in the sharp declines of 2023.
Return on Assets (ROA)
The reported ROA shows an upward trend from 7.72% in 2020 to 13.3% in 2022, followed by a dramatic drop to 0.34% in 2023 and then a recovery to 14.62% in 2024. Adjusted ROA mirrors this pattern but at consistently higher levels, increasing from 9.9% in 2020 to 16.51% in 2022, dropping significantly to 0.43% in 2023, and rebounding to 17.94% in 2024. This pattern highlights a significant dip in asset profitability in 2023, which is apparent in both reported and adjusted measures, and a strong recovery in the subsequent year. The adjusted figures underscore the importance of asset base adjustments in evaluating true asset efficiency.

Merck & Co. Inc., Financial Ratios: Reported vs. Adjusted


Adjusted Total Asset Turnover

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Sales
Total assets
Activity Ratio
Total asset turnover1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Sales
Adjusted total assets
Activity Ratio
Adjusted total asset turnover2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Total asset turnover = Sales ÷ Total assets
= ÷ =

2 Adjusted total asset turnover = Sales ÷ Adjusted total assets
= ÷ =


The data indicates an overall upward trend in both reported and adjusted total assets from 2020 to 2024. Reported total assets increased steadily from US$91,588 million in 2020 to US$117,106 million in 2024, showing consistent growth with a minor decline in 2023. Adjusted total assets, which exclude goodwill, also rose from US$71,350 million to US$95,438 million over the same period but exhibited a slight dip in 2023.

Regarding asset efficiency, the reported total asset turnover ratio shows some fluctuation but remains fairly stable, ranging from 0.46 to 0.56. It dropped in 2021 to 0.46 but increased afterward, peaking at 0.56 in 2023 before a slight decline in 2024 to 0.55. This suggests that the company maintained its ability to generate sales from its total assets with minor variation over the years.

The adjusted total asset turnover ratio demonstrates higher values than the reported one, reflecting greater efficiency when excluding goodwill from assets. This ratio fell from 0.67 in 2020 to 0.58 in 2021 but rebounded to 0.70 in 2023 before settling at 0.67 in 2024. The trend indicates a robust capacity to generate revenue from tangible assets, with notable resilience despite some year-to-year variability.

Total Assets
The growth in reported total assets suggests expanding asset base over the five years, while the adjusted total assets, excluding goodwill, show a parallel trend albeit at a lower magnitude.
Asset Turnover Ratios
The stability in reported total asset turnover indicates consistent utilization of total assets in revenue generation. The higher adjusted total asset turnover ratios imply relatively efficient use of tangible assets without the effect of goodwill.
Fluctuations
The dip in total assets and turnover ratios observed around 2021 and 2023 highlights some temporary impacts on asset size or efficiency, which the company appears to have managed effectively given the recovery in subsequent years.

Adjusted Financial Leverage

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Total assets
Total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Financial leverage1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Adjusted total assets
Adjusted total Merck & Co., Inc. stockholders’ equity
Solvency Ratio
Adjusted financial leverage2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 Financial leverage = Total assets ÷ Total Merck & Co., Inc. stockholders’ equity
= ÷ =

2 Adjusted financial leverage = Adjusted total assets ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= ÷ =


Analysis of the financial data reveals several notable trends related to total assets, stockholders’ equity, and financial leverage over the five-year period.

Total Assets
Reported total assets increased overall from 91,588 million US dollars in 2020 to 117,106 million US dollars in 2024, with a dip observed in 2023. Adjusted total assets, which exclude goodwill, followed a similar upward trend, rising from 71,350 million to 95,438 million US dollars during the same period, but also experienced a decrease in 2023.
Stockholders’ Equity
Reported stockholders’ equity showed strong growth, increasing from 25,317 million US dollars in 2020 to 46,313 million US dollars in 2024. However, there was a decrease in 2023 compared to the previous year. Adjusted stockholders’ equity, which accounts for goodwill adjustments, demonstrated a parallel pattern, growing from 5,079 million to 24,645 million US dollars with a decline in 2023 similar to the reported figures.
Financial Leverage
The reported financial leverage ratios decreased from 3.62 in 2020 to 2.53 in 2024, although there was an increase noted in 2023. The adjusted financial leverage ratios, accounting for goodwill exclusions, were significantly higher but showed a marked decline from 14.05 in 2020 to 3.87 in 2024. There was also an increase in 2023, indicating a temporary rise in leverage before returning to a declining trend.

Overall, the data suggest that the company experienced growth in assets and equity over the period, with a temporary setback in 2023. The financial leverage ratios indicate a general trend toward lower leverage, especially after adjusting for goodwill, despite the intermittent increases in 2023. The disparity between reported and adjusted figures underscores the substantial impact of goodwill on the balance sheet and leverage metrics.


Adjusted Return on Equity (ROE)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
ROE1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Adjusted total Merck & Co., Inc. stockholders’ equity
Profitability Ratio
Adjusted ROE2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =

2 Adjusted ROE = 100 × Net income attributable to Merck & Co., Inc. ÷ Adjusted total Merck & Co., Inc. stockholders’ equity
= 100 × ÷ =


Trends in Reported Total Stockholders’ Equity
The reported total stockholders’ equity exhibited a generally upward trend from 2020 through 2024, beginning at $25,317 million in 2020 and reaching $46,313 million by 2024. A noticeable increase occurred from 2020 to 2022, where equity rose significantly to $45,991 million. However, in 2023 a decline was observed, dropping to $37,581 million before rebounding to $46,313 million in 2024, nearly matching the 2022 peak.
Trends in Adjusted Total Stockholders’ Equity
The adjusted total stockholders’ equity also showed substantial growth over the period, despite lacking absolute consistency. Starting at a low base of $5,079 million in 2020, the figure increased markedly to $24,787 million by 2022. A reduction followed in 2023 to $16,384 million, paralleling the trend observed in reported equity. The adjusted equity then rose again in 2024 to $24,645 million, slightly below the 2022 level but demonstrating recovery after the 2023 dip.
Reported Return on Equity (ROE) Patterns
The reported ROE maintained strong performance from 2020 through 2022, with values ranging from around 28% to 32%, peaking at 34.17% in 2021. However, in 2023 there was a sharp decline to 0.97%, indicating a significant weakening in profitability relative to reported equity. This decline was short-lived as the ROE substantially increased again to 36.96% in 2024, reaching the highest recorded level over the period.
Adjusted Return on Equity (ROE) Patterns
The adjusted ROE showed very high values in 2020 at 139.14%, reflecting strong profitability relative to the adjusted equity base at that time. This measure declined steadily through 2022 to 58.58%, followed by a pronounced decrease in 2023 to 2.23%, closely mirroring the drop seen in the reported ROE. In 2024, the adjusted ROE rebounded to 69.45%, indicating improved profitability in relation to adjusted equity but remaining significantly lower than the initial 2020 value.
Overall Insights
Both reported and adjusted stockholders’ equity experienced significant growth from 2020 to 2022, followed by a marked decline in 2023 and a recovery in 2024. This pattern is also reflected in ROE metrics, where profitability remained high early on, plummeted in 2023, and then recovered the following year. Notably, adjusted figures show higher volatility, with adjusted ROE starting from an exceptionally high baseline and then adjusting downwards over time, highlighting the impact of goodwill adjustments on equity and profitability measures. The 2023 declining trend in both equity and ROE suggests an event or series of events that negatively impacted financial performance or equity valuation, but the recovery in 2024 indicates a return to more favorable conditions.

Adjusted Return on Assets (ROA)

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
As Reported
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Total assets
Profitability Ratio
ROA1
Adjusted for Goodwill
Selected Financial Data (US$ in millions)
Net income attributable to Merck & Co., Inc.
Adjusted total assets
Profitability Ratio
Adjusted ROA2

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

2024 Calculations

1 ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Total assets
= 100 × ÷ =

2 Adjusted ROA = 100 × Net income attributable to Merck & Co., Inc. ÷ Adjusted total assets
= 100 × ÷ =


Total Assets
The reported total assets show a generally increasing trend over the five-year period, rising from $91,588 million in 2020 to $117,106 million in 2024. There is a slight decrease observed in 2023, where reported assets declined to $106,675 million from $109,160 million in 2022, before increasing again in 2024.
The adjusted total assets, which exclude goodwill, follow a similar overall upward trend, moving from $71,350 million in 2020 to $95,438 million in 2024. Like the reported total assets, there is a decline in adjusted assets in 2023, dropping to $85,478 million from $87,956 million the previous year, but increasing thereafter.
Return on Assets (ROA)
The reported ROA displays a rising trend from 7.72% in 2020 to a peak at 13.3% in 2022. In 2023, there is a marked decline to 0.34%, followed by a recovery to 14.62% in 2024, indicating significant volatility in that year.
The adjusted ROA, which accounts for the exclusion of goodwill, mirrors the trend of the reported ROA but at consistently higher levels. It increases from 9.9% in 2020 to 16.51% in 2022, then sharply declines to 0.43% in 2023. The ratio recovers strongly to 17.94% in 2024, surpassing previous highs. This suggests that the operational performance excluding goodwill shows greater returns and similar volatility during the period.